Announced Fri, 24 Jul · 09:49 IST
Subsidiary gets GST show cause notice for Rs 4.06 crore ITC dispute
Regulatory & Legal View source PDF
PANACEABIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-3.0%1-day move
₹445.50
prior close
₹438.05
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.3-0.7-0.7-0.6-3.0—————————
Up moveDown movePending
AI summary
Panacea Biotec's wholly owned subsidiary Panacea Biotec Pharma Ltd has received a GST Show Cause Notice dated July 23, 2026 from the Assistant Commissioner in Delhi. The notice alleges a total tax liability of Rs 4.06 crore (tax Rs 2.27 crore, interest Rs 1.56 crore, penalty Rs 0.23 crore) over excess claim of Input Tax Credit in the FY2022-23 annual return. The subsidiary is preparing its response and says no material adverse impact on financial or operations is expected.
Likely market impact
Tax dispute is at notice stage only, not a confirmed liability. Amount is modest. Watch for response outcome and any escalation.